Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and...
2 hours ago
KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks
Ben Palleiko is asked about the company's take on headlines that were in the news during the FDA review of the drug, and he describes the...
3 days ago
AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery
Co-Founder & CEO Peter Fedichev describes why he believes reading the amino acid sequences that have been written into the human genome...
Jun 30
ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features
He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same...
Jun 27
Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year
Josh Cohen and Justin Klee walk us through the lead program, avexitide, which is a GLP-1 antagonist and is currently in a pivotal study...
Jun 25
Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis
CEO Paul Higham describes the biology of GPR65 inhibition, something that pharma companies have previously tried to do, and explains how...
Jun 24
AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets
Co-Founder Linda Goodman describes the product and the numerous components that go into the scoring.
Jun 20
AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences
Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an...
Jun 19
Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited
An Operating Partner at SV Health Investors, she describes how the company came together after reaching out to Cardiff University...
Jun 18
BIO International 2025: Sweden's Alligator has a phase three ready CD40 asset for pancreatic cancer and is looking for a partner to move it forward
CEO Søren Bregenholt describes Alligators phase 2 data, as well as regulatory feedback it has received regarding the phase three trial...
Jun 18
BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy
Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for,...
Jun 18
Cardiff-based Draig Therapeutics launched today in the neuro space with a total investment of $140 million, with lead program DT-101, an AMPA receptor PAM, ready for P2 in Major Depressive Disorder
Professor Simon Ward of Cardiff University’s Medicines Discovery Institute, and Scientific Co-founder and CSO Draig, describes the...
Jun 18
BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs
He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short...
Jun 17
BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions
He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs....
Jun 17
BIO International 2025: Germany's Aicuris, a company that focuses on helping immunocompromised patients, has breakthrough therapy designation for its HSV treatment that is in a pivotal
CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS),...
Jun 17
BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple...
Jun 16
BIO International 2025: CEO Steve Favaloro introduces us to Genezen - a best-in-class CDMO with a preclinical to commercial offering
From the floor of the BIO International Convention, he describes the services that Genezen offers, its growth, and how it can partner...
Jun 16
BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next
He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is...
Jun 16
BIO International 2025: Ocugen CEO Shankar Musunuri discusses the company's gene therapy platform for eye conditions - one of which is already in a pivotal, with another to start
He discusses the company's gene therapy approach to retinitis pigmentosa, Stargardt disease (which just had a pivotal cleared by FDA...
Jun 16
Welcoming Genezen to the BiotechTV family today as a new sponsor
Genezen is a best-in-class CDMO with over a decade of experience and state-of-the-art viral vector facilities. Genezen's advanced...
Jun 16
EHA 2025: Arcellx CEO Rami Elghandour discusses the results presented today of the iMMagine-1 Study for the company's BCMA CAR-T
He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market,...
Jun 14
EHA 2025: The CEO of Ascentage Pharma, which had its U.S. IPO earlier this year, introduces us to the company and discusses BCR-ABL, Bcl-2, and EED targeting programs
Dajun Yang shares the history of Ascentage, talks about what makes the BCR-ABL program, which Takeda took an option on, a...
Jun 14
EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA
CMO Gianfranco Pittari walks us through data from the pivotal ARES study that MaaT announced in January and filed with the EMA. Plus, an...
Jun 14
EHA 2025: CEO Arthur Sands discusses Nurix Therapeutics' BTK degrader data, the development plan ahead, recent #AACR25 data regarding brain penetration, and activity in the autoimmune space
He discusses the P1 data presented at EHA for CLL and WM, which he says showed efficacy across mutations, durability, and clean safety....
Jun 13
EHA 2025: CEO Jonathan Dickinson discusses Innate Pharma's NK cell engager platform (ANKET), recent ASCO data for Lacutamab, and other program updates
He describes Innate's NK cell platform and covers programs targeting CD20, CD123, BCMA, and B7-H3. Plus Lacutamab data, updates on the...
Jun 13
CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction
CEO Leff Luber describes the tool, which is mean to augment a radiologist's analysis, and how its modeling algorithm takes into account...
Jun 11
Cullinan Therapeutics' CEO Nadim Ahmed covers last week's #ASCO25 data for zipalertinib in EGFRex20 insertion lung cancer, plus an in-depth conversation about bispecifics for autoimmune conditions
He highlights the zipalertinib ASCO data, which was in the relapsed setting and will be used by Cullinan's partner, Taiho, to file for...
Jun 10
AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy
CMO Tim Showalter describes the finding, which was selected as a "Best of ASCO" oral presentation. Plus, helping to determine how certain...
Jun 6
.png){kind=logo}
